Prevalence of Symptomatic Vitreomacular Adhesion in 9 Major Markets 2016-2026
Symptomatic Vitreomacular adhesion (VMA) is a rare macular condition caused by an incomplete posterior vitreous detachment from the retina, located at the back of the eye, with remaining vitreomacular attachment and unperturbed foveal morphologic features. It is almost always the result of normal vitreous aging, and is termed symptomatic VMA leading to vitreomacular traction because with loss of vitreous volume, these areas of VMA exert a “pulling force” on the macula, causing other pathologic conditions.
This report provides the current prevalence for symptomatic VMA across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of VMA have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for VMA include:
- Decreased visual acuity
- Retinal distortion and disruption
- Post-menopause (females)
- Macular oedema
- Macular hole
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
- Able to quantify patient populations in global symptomatic VMA’s market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the prevalence of the subdivided types of symptomatic VMA and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Provide a level of understanding on the impact from specific co-morbid conditions on symptomatic VMA’s prevalence.
- Identify sub-populations within symptomatic VMA which require treatment.
- Gain an understanding of the specific markets that have the largest number symptomatic VMA patients.
You may also like…
A robust source of evidence-based patients for diseases, hospital admissions and procedures across healthcare markets.